Voluntary nationwide recall: Sodium Bicarb and Atropine (Hospira – December)
Jan. 2024Pharmacy Updates
Hospira Inc. is recalling several lots of 4.2% Sodium Bicarbonate Injection, USP, 8.4% Sodium Bicarbonate Injection, USP, and Atropine Sulfate Injection, USP. Sodium Bicarbonate is used for the treatment of metabolic acidosis (a buildup of acid in the body). Atropine Sulfate is used for temporary blockade of severe or life-threatening muscarinic effects (effects on certain nerves of the body).
These drugs are being recalled because particles of glass were found in the drug(s) during a routine inspection of samples. Administration of an injectable product that contains particulate matter may result in local irritation or swelling, blockage of blood vessels, or life-threatening blood clot events.
As of the date of Hospira’s recall announcement, Dec. 21, 2023, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below. If you have an affected lot of Sodium Bicarbonate Injection or Atropine Sulfate Injection, you should stop using the item and return it to the place of purchase or discard it. To learn more about this recall, you can take one or more of the steps below.
These drugs are being recalled because particles of glass were found in the drug(s) during a routine inspection of samples. Administration of an injectable product that contains particulate matter may result in local irritation or swelling, blockage of blood vessels, or life-threatening blood clot events.
As of the date of Hospira’s recall announcement, Dec. 21, 2023, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below. If you have an affected lot of Sodium Bicarbonate Injection or Atropine Sulfate Injection, you should stop using the item and return it to the place of purchase or discard it. To learn more about this recall, you can take one or more of the steps below.
- Talk to your doctor or pharmacist.
- Call Sedgwick Inc. at 1-800-805-3093. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. EST.
- Visit the FDA website.
Recent Announcements
Voluntary nationwide recall: Sucralfate (Nostrum – July)
Nostrum Laboratories, Inc. is recalling all lots of Sucralfate Tablets USP 1 gram. Sucralfate is used for the prevention and treatment of certain stomach ulcers.Jul. 2025Pharmacy Updates
Receive consultations to better support the behavioral health needs of child and adolescent patients
The Telephonic Psychiatric Consultation Service Program (TiPS) is a Pennsylvania HealthChoices program that gives primary care providers access to free, on-demand consultations with child and adolescent psychiatrists, typically within 30 minutes. It is available to providers of children and adolescents who have Pennsylvania Medicaid, Children’s Health Insurance Program, or UPMC Health Plan commercial insurance.Jul. 2025What's New
Voluntary nationwide recall: Sucralfate (Nostrum – July)
Nostrum Laboratories, Inc. is recalling all lots of Sucralfate Tablets USP 1 gram. Sucralfate is used for the prevention and treatment of certain stomach ulcers.Jul. 2025Pharmacy Updates